ARCA biopharma (FRA:HQ10) Future 3-5Y EPS without NRI Growth Rate : N/A (As of May. 05, 2025)

View and export this data going back to 1997. Start your Free Trial

What is ARCA biopharma Future 3-5Y EPS without NRI Growth Rate?

Future 3-5Y EPS without NRI Growth Rate is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

As of today, ARCA biopharma's Future 3-5Y EPS without NRI Growth Rate is N/A.

Competitive Comparison of ARCA biopharma's Future 3-5Y EPS without NRI Growth Rate

For the Biotechnology subindustry, ARCA biopharma's Future 3-5Y EPS without NRI Growth Rate, along with its competitors' market caps and Future 3-5Y EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ARCA biopharma's Future 3-5Y EPS without NRI Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ARCA biopharma's Future 3-5Y EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where ARCA biopharma's Future 3-5Y EPS without NRI Growth Rate falls into.

Save Embed

;

Save Embed

;

ARCA biopharma (FRA:HQ10) Future 3-5Y EPS without NRI Growth Rate Explanation

Future 3-5Y EPS without NRI Growth Rate s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.

ARCA biopharma Future 3-5Y EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of ARCA biopharma's Future 3-5Y EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

ARCA biopharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ARCA biopharma Inc (FRA:HQ10) » Definitions » Future 3-5Y EPS without NRI Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

10170 Church Ranch Way, Suite 100, Westminster, CO, USA, 80021

Website

https://www.arcabio.com

ARCA biopharma Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to the development and commercialization of targeted therapies for cardiovascular diseases. The company's product candidates are rNAPc2 as a potential treatment for COVID-19, the disease syndrome caused by the SARS-CoV-2 virus, and potentially other viral diseases and Gencaro for the treatment of atrial fibrillation, or AF, in patients with chronic heart failure, or HF. rNAPc2 targets COVID-19 patients with biomarker evidence of coagulopathy, while Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy.

ARCA biopharma Headlines

No Headlines